hotspot -WSS

hotspot

author：comprehensive 2025-08-19 12:15:42 - browse：3

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

focus

WSS

Fetal surgery at risk from Dobbs and new abortion restrictions

The surgeon had a dilemma only a Nazi medical text could resolve

Mayo Clinic plans $5B tech

Why doctors need education on FDA device approval process

Independent physicians launch a new lobbying group

How digital therapeutics firms are pivoting after Pear's bankruptcy

entertainment

hotspot

hotspot

Supreme Court strikes down use of affirmative action

New brain studies show LSD's effects on the brain in full color

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

eGenesis tests gene

Trump demands the U.S. pay no more for drugs than other countries … again

BIO selects John Crowley as new CEO

Hollywood unions extend contract negotiations for actors

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Virginia high school admissions case could be legal follow

Flagship Pioneering launches a new biotech in two countries

focus

The surgeon had a dilemma only a Nazi medical text could resolve

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Copay coupons to count toward deductibles, after Biden court move

Pediatric cancer treatments threatened by a new FDA policy

BIO selects John Crowley as new CEO

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

leisure time

entertainment

focus

entertainment